KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Xenon Pharmaceuticals (XENE) Return on Invested Capital: 2019-2024

Historic Return on Invested Capital for Xenon Pharmaceuticals (XENE) over the last 4 years, with Sep 2024 value amounting to -0.31%.

  • Xenon Pharmaceuticals' Return on Invested Capital was N/A to -0.31% in Q3 2024 from the same period last year, while for Sep 2024 it was -0.31%, marking a year-over-year change of. This contributed to the annual value of -0.26% for FY2023, which is N/A change from last year.
  • As of Q3 2024, Xenon Pharmaceuticals' Return on Invested Capital stood at -0.31%, which was down 13.39% from -0.27% recorded in Q2 2024.
  • In the past 5 years, Xenon Pharmaceuticals' Return on Invested Capital ranged from a high of -0.13% in Q2 2022 and a low of -0.31% during Q3 2024.
  • Over the past 3 years, Xenon Pharmaceuticals' median Return on Invested Capital value was -0.25% (recorded in 2024), while the average stood at -0.22%.
  • In the last 5 years, Xenon Pharmaceuticals' Return on Invested Capital rose by 28bps in 2020 and then decreased by 10bps in 2021.
  • Over the past 5 years, Xenon Pharmaceuticals' Return on Invested Capital (Quarterly) stood at -0.18% in 2020, then fell by 2bps to -0.20% in 2021, then rose by 12bps to -0.14% in 2022, then reached -0.27% in 2023, then reached -0.31% in 2024.
  • Its Return on Invested Capital stands at -0.31% for Q3 2024, versus -0.27% for Q2 2024 and -0.25% for Q1 2024.